S-1/A: Entero Therapeutics Seeks $6 Million Capital Raise Amid Strategic Shift and Financial Challenges

Entero Therapeutics, Inc. is offering 12 million shares of common stock or pre-funded warrants to raise approximately $6 million, primarily to fund its lead drug candidate Adrulipase and address significant financial liabilities, while also unwinding a recent merger with ImmunogenX, Inc.

Summary

• Entero Therapeutics, Inc. (formerly First Wave Biopharma, Inc.) is a biopharmaceutical company focused on developing non-systemic therapies for gastrointestinal diseases, with its primary focus now on Adrulipase.
• The company is offering 12,000,000 shares of common stock or pre-funded warrants at an estimated public offering price of $0.50 per share, aiming to raise approximately $4 million in net proceeds.
• Proceeds are intended for marketing ($1.5 million), repayment of outstanding liabilities (up to $1.1 million, including $695,000 of ImmunogenX, LLC accounts payable if rescission closes), and advancing the Adrulipase program ($1.4 million).
• The company recently entered into a rescission agreement to unwind its March 2024 merger with ImmunogenX, LLC (IMGX), which was developing Latiglutenase for celiac disease and CypCel.
• The rescission aims to eliminate secured debt obligations associated with IMGX (approximately $2.44 million) and allow Entero to focus its limited resources on Adrulipase.
• Entero Therapeutics has incurred significant operating losses and negative cash flows since inception, with an accumulated deficit of approximately $203.6 million as of March 31, 2025, and cash and cash equivalents of only $66,000.
• The company received 'going concern' qualifications in its 2023 and 2024 audits, indicating substantial doubt about its ability to continue operations without additional funding.
• Adrulipase, a therapy for exocrine pancreatic insufficiency (EPI) in cystic fibrosis (CF) and chronic pancreatitis (CP) patients, had mixed Phase 2b monotherapy results (mean CFA 50.6%-66% vs. target >=80%) but positive Phase 2 combination therapy results (average CFA gain >6 percentage points).
• The Latiglutenase program (IMGX asset) was discontinued due to insufficient efficacy for FDA approval and high estimated Phase 3 costs ($30 million) for a non-core asset.
• The company has reduced its full-time employee headcount from 15 (March 31, 2024) to 2 (June 16, 2025) due to capital constraints.
• Entero Therapeutics faces multiple Nasdaq listing compliance issues, including minimum bid price, stockholders' equity, and annual meeting requirements, with a risk of delisting.
• A lawsuit from Ellenoff Grossman & Schole LLP for $749,301 in unpaid legal fees is ongoing, with the company evaluating claims and negotiating settlement.

Sentiment

Score: 2

Explanation: The sentiment is overwhelmingly negative due to severe financial distress (low cash, high accumulated deficit, going concern warnings), significant operational cutbacks (employee reduction), and multiple Nasdaq non-compliance issues with delisting risk. While the strategic refocusing and rescission of the IMGX merger are positive steps, they are reactive measures to a dire situation. The failure of the Adrulipase monotherapy trial is a major setback, and the need for immediate and future capital raises highlights extreme dependency on external funding with no guarantee of success.

Positives

• The company is strategically refocusing its efforts and limited resources on its lead drug candidate, Adrulipase, by unwinding the ImmunogenX merger.
• The rescission agreement, if consummated, will eliminate approximately $2.44 million in secured debt obligations associated with ImmunogenX, significantly improving the balance sheet and financial flexibility.
• The Adrulipase program has shown positive results in a Phase 2 combination therapy trial, demonstrating clinically meaningful improvements in Coefficient of Fat Absorption (CFA) and other secondary endpoints.
• Adrulipase addresses a significant unmet medical need in well-defined patient populations (40,000+ CF patients, 300,000-500,000 CP patients in the US with EPI), with a large existing market for current treatments (PERTs, $2.1 billion in 2024).
• The company has a robust intellectual property portfolio for Adrulipase, with patents extending to 2043 and expected 12-year biologic exclusivity in the US and 10-year data exclusivity in the EU.
• The settlement of the Mattress Liquidators lawsuit, with Dr. Syage assuming primary responsibility for the debt, reduces a significant contingent liability for the company, provided the rescission closes.

Negatives

• The company has incurred significant operating losses and negative cash flows since inception, with an accumulated deficit of approximately $203.6 million as of March 31, 2025.
• Cash and cash equivalents were critically low at approximately $66,000 as of March 31, 2025.
• The company received 'going concern' qualifications in its audits for the financial years ended December 31, 2024, and 2023, indicating substantial doubt about its ability to continue operations.
• The Phase 2b pilot monotherapy study for Adrulipase did not meet its primary efficacy endpoint, with mean CFAs significantly below the targeted 80%.
• The Latiglutenase program, acquired through the ImmunogenX merger, was discontinued due to insufficient efficacy for FDA approval and high estimated Phase 3 costs of up to $30 million.
• The company's market capitalization was approximately $1.6 million as of December 31, 2024, reflecting its distressed financial state.
• Employee headcount has been drastically reduced from 15 to 2 full-time employees due to significant capital constraints.
• If the ImmunogenX rescission agreement is not consummated, the company will be liable for approximately $2.44 million of ImmunogenX's secured debt and an additional $46,000 of accounts payable, and faces potential new litigation from Mattress Liquidators, Inc.
• The company is facing a lawsuit from Ellenoff Grossman & Schole LLP for $749,301 in unpaid legal fees.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to significant operating losses, negative cash flows, and dependence on external funding.
• Failure to obtain additional working capital funding from equity and/or debt securities could force the company to delay, limit, or terminate operations, reduce workforce, or seek bankruptcy protection.
• The Pre-funded Warrants will not be listed or quoted on any exchange, limiting their liquidity.
• New investors will experience immediate and substantial dilution of $0.46 per share due to the offering price being substantially higher than the net tangible book value per share.
• Failure to maintain compliance with Nasdaq's continued listing requirements (minimum bid price, stockholders' equity, annual meeting) could result in delisting of the common stock.
• If the common stock is delisted, trading would likely move to an over-the-counter market, reducing liquidity and potentially affecting the ability to raise capital.
• If the transactions under the Rescission Agreement are not consummated, the company will be liable for approximately $2,436,338 of ImmunogenX, LLC's secured debt and an additional $46,000 of its accounts payable, and may face a new lawsuit from Mattress Liquidators, Inc.
• The company may be required to settle potential conversion of Series G Preferred Stock in cash if shareholder approval for conversion into common stock is not obtained.
• Management has broad discretion over the use of net proceeds from the offering, which may not necessarily increase operating results or market value.
• Additional capital will be needed to begin a Phase 3 clinical trial for Adrulipase, and there is no assurance such funding will be available on acceptable terms or at all.

Future Outlook

Entero Therapeutics anticipates having sufficient cash to fund planned operations through April 2026, assuming successful financing efforts and the closing of the Rescission Agreement. If the rescission is not consummated, this runway shortens to approximately six months. The company plans to seek follow-on financing by the end of the third quarter of 2025, solely to fund Phase 3 trials for Adrulipase. They are planning to move the Adrulipase program forward in 2025, including initiating a Phase 2b clinical trial in the second half of 2025.

Management Comments

• "We believe that this strategic refocusing is supported by multiple business and financial considerations." (Regarding rescinding IMGX merger)
• "The Company expects that the closing of the Rescission Agreement will occur on or prior to June 30, 2025, subject to satisfaction of all conditions for closing, including obtaining shareholder approval."
• "We believe that additional capital will be needed to begin a Phase 3 clinical trial for Adrulipase. In this regard, we plan to seek follow-on financing by the end of the third quarter of 2025, which will be used solely to fund the Phase 3 trials."
• "Our management will have broad discretion in the application of the net proceeds, and investors will be relying on our judgment regarding the application of the net proceeds from this offering."
• "We believe that the net proceeds of this offering, accounting for payments made to IR Agency LLC and together with our existing cash, will enable us to fund our operations for at least ten (10) months following the completion of this offering." (If rescission consummated)
• "We believe that the net proceeds of this offering, accounting for payments made to IR Agency LLC and together with our existing cash, will enable us to fund our operations for at least six (6) months following the completion of this offering." (If rescission not consummated)
• "We believe that the underlying cause of the drugs uneven performance in the OPTION 2 trial was the enteric capsule formulation."
• "Although the primary efficacy endpoint was not achieved, we believe that this may be on account of issues with quality control and clinical approach related to the study." (Regarding Adrulipase Phase 2b monotherapy)

Industry Context

Entero Therapeutics operates in the biopharmaceutical sector, specifically targeting gastrointestinal diseases with non-systemic therapies. Its primary drug candidate, Adrulipase, aims to treat Exocrine Pancreatic Insufficiency (EPI) in patients with cystic fibrosis (CF) and chronic pancreatitis (CP). This market is currently dominated by porcine pancreatic enzyme replacement therapies (PERTs), which generated an estimated $2.1 billion in sales in the U.S. in 2024 and have been growing at a compound annual growth rate of approximately 20%. Adrulipase seeks to offer a non-animal derived alternative with the potential to reduce daily pill burden, addressing limitations of current PERTs such as poor stability, formulation problems, and potential transmission of infectious agents. The company's strategic shift to focus solely on Adrulipase reflects a move towards a more specialized and capital-efficient approach within the GI therapeutic space, abandoning broader programs like celiac disease (Latiglutenase) and gastroparesis (Capeserod) that were deemed less aligned with core competencies or too costly for their potential efficacy.

Comparison to Industry Standards

• Adrulipase's Phase 2b pilot monotherapy study showed mean Coefficient of Fat Absorption (CFA) of 66% (2240 mg/day dose) and 53% (4480 mg/day dose DR formulation), and 52.9% (4.4g/day) and 50.6% (6.6g/day) for IR formulations. These results did not meet the targeted CFA of >=80%, which is generally considered indicative of adequate fat absorption in this patient population, and were lower than standard porcine pancreatic enzyme replacement therapy (PERT) which achieved mean CFAs of approximately 86% in previous comparator trials (e.g., Study AZ-CF2001).
• In contrast, the Adrulipase Phase 2 Combination Trial (Adrulipase + PERT) demonstrated clinically meaningful improvements in CFA, with patients showing an average gain of more than six percentage points from baseline, compared to the five-point improvement in CFA cited by clinical literature as clinically significant.
• Latiglutenase, the divested asset, showed positive impact on reducing small intestinal damage by 60-88% in celiac patients in Phase 2 data, but faced insufficient efficacy for FDA approval as a 2022 study found no statistically significant improvement in serology markers (tTG-IgA, DGP-IgA/IgG) compared to placebo. A Phase 3 trial design for Latiglutenase, while FDA-reviewed, required enrollment of 1,200 patients, representing a significant capital investment (estimated up to $30 million) and high execution risk, making it less viable compared to the company's core Adrulipase program which targets larger patient populations and has clearer regulatory pathways in the company's opinion.

Management Changes

Corporate Governance

Legal Proceedings

• **Mattress Liquidators, Inc. vs. ImmunogenX, LLC, Jack A. Syage, and The Jack A. Syage and Elizabeth T. Syage Revocable Trust:** Filed December 31, 2024, in Colorado, alleging non-payment of a loan totaling $7,575,568.91 as of that date. A settlement agreement was reached on April 9, 2025 (executed May 8, 2025), where Dr. Syage and his Trust agreed to pay $5.5 million of the approximately $7.9 million owed, and ImmunogenX agreed to pay $62,000 in legal fees. A new revolving loan of $2,436,338.30 was established for ImmunogenX, LLC, guaranteed by Dr. Syage. The company will have no further duties or liabilities related to this complaint if the rescission agreement is consummated.
• **Ellenoff Grossman & Schole LLP (EGS) vs. Entero Therapeutics, Inc.:** Filed March 17, 2025, in New York, seeking $749,301.00 for unpaid legal fees, costs, and disbursements for services rendered from September 2023 through January 2025. The company is currently evaluating the claims and defenses and is in negotiations with EGS to settle the lawsuit.

Related Party Transactions

• Dr. Jack Syage, a director and Chief Scientific Officer of the company, was a principal of ImmunogenX, Inc. (IMGX) and a former IMGX shareholder. He transitioned from COO to CSO on June 17, 2024.
• As part of the original merger, the company issued 36,830 shares of common stock and 11,777.418 shares of Series G Preferred Stock to former IMGX shareholders, including Dr. Syage.
• In connection with the merger, the company issued 18,475 shares of Common Stock and 595.808 shares of Series G Preferred Stock to a consultant (Tungsten Capital Partners LP) for services relating to the merger.
• Dr. Syage and The Jack A. Syage and Elizabeth T. Syage Revocable Trust were co-defendants with ImmunogenX, LLC in the Mattress Liquidators, Inc. lawsuit and are the guarantors of the secured debt owed by ImmunogenX, LLC.
• Under the April 9, 2025 settlement agreement with Mattress Liquidators, Inc., Dr. Syage and his Trust agreed to pay $5.5 million of the approximately $7.9 million owed, and they unconditionally guaranteed the prompt payment of all monies owed by ImmunogenX, LLC under the amended and restated loan documents.
• Following the consummation of the Rescission Agreement, Dr. Jack Syage and his affiliated entities, as IMGX Shareholders, will own approximately 42% of the transferred membership interests of ImmunogenX, LLC.
• If the rescission is not consummated, the company would be liable for amounts due under two unsecured promissory notes issued to Dr. Jack Syage and Peter Felker, each at a rate of 13% and maturing on September 30, 2025.

Stakeholder Impact

• **Shareholders:** Face immediate and substantial dilution from the current offering. Existing shareholders are at risk of significant value loss due to the company's 'going concern' issues, recurring losses, and potential delisting from Nasdaq. The strategic shift and debt reduction from the rescission, if successful, could provide long-term stability but are subject to shareholder approval and execution risks.
• **Employees:** The drastic reduction in full-time employees from 15 to 2 indicates severe job insecurity and a highly constrained operational environment. Remaining employees face high pressure and limited resources.
• **Customers/Patients:** The focus on Adrulipase aims to provide a non-animal derived, potentially less burdensome therapy for EPI patients, which could be a positive long-term impact if successful. However, the pause in drug development and mixed trial results for Adrulipase monotherapy introduce uncertainty regarding future product availability.
• **Suppliers/Creditors:** The company has significant outstanding liabilities, including accounts payable and legal fees. The ongoing negotiations with Ellenoff Grossman & Schole LLP and the settlement with Mattress Liquidators, Inc. (with Dr. Syage assuming much of the liability) directly impact these creditors. The company's ability to pay its obligations is highly dependent on successful capital raises.
• **Regulatory Authorities (FDA, Nasdaq):** The company is actively engaging with the FDA regarding Adrulipase's next steps. Compliance with Nasdaq listing rules is a critical ongoing challenge, with potential delisting impacting market integrity and investor confidence.

Next Steps

• Deliver the securities offered to investors on or about the specified date in 2025.
• Obtain shareholder approval for the transfer of ImmunogenX, LLC membership interests to the IMGX Shareholders to consummate the Rescission Agreement on or prior to June 30, 2025.
• Use net proceeds from the offering to fund marketing, repay liabilities (including IMGX accounts payable if rescission closes), and advance the Adrulipase program.
• Hold a Type C meeting with the FDA to discuss next steps for the Adrulipase program.
• Initiate a Phase 2b clinical trial for Adrulipase in the second half of 2025.
• Seek follow-on financing by the end of the third quarter of 2025, solely to fund Phase 3 trials for Adrulipase.
• Monitor the closing bid price of common stock and consider options to regain Nasdaq minimum bid price compliance by September 1, 2025.
• Regain compliance with Nasdaq's annual meeting requirement by June 30, 2025.
• Regain compliance with Nasdaq's minimum stockholders' equity requirement after submitting a plan within 45 days of the April 11, 2025 notice.
• Continue evaluating claims and negotiating settlement with Ellenoff Grossman & Schole LLP regarding unpaid legal fees.

Key Dates

Recommendation

Keywords

Biopharmaceutical, Gastrointestinal diseases, Adrulipase, Exocrine Pancreatic Insufficiency, Cystic Fibrosis, Chronic Pancreatitis, SEC filing, S-1/A, Public offering, Pre-funded warrants, Capital raise, Going concern, Nasdaq compliance, Merger rescission, ImmunogenX, Latiglutenase, Clinical trials, Drug development, Financial distress, Biotech